Managed Healthcare Executive November 22, 2021
Momentum is building for biosimialrs but robust coverage for lower-cost agents, including biosimilars, is needed.
Six years after the first biosimilar was approved by the FDA, the U.S. is on the verge of finally realizing the broad benefits these products can bring to patients across a range of therapeutic areas.
2021 has been particularly strong for the growth of biosimilars in oncology, led by biosimilars referencing major therapeutic oncology products Avastin, Herceptin, and Rituxan. With added government support through bills such as the Advancing Education on Biosimilars Act of 2021, and new proposed legislation including the HHS response letter to the July 9th Executive Orders, biosimilars remain a primary focus from a policy perspective.
In addition to new policies, the...
Today's Sponsors
Today's Sponsor